Key Points
- Halozyme CEO Helen Torley sold 10,000 shares on April 6 at $63.50 for $635,000, leaving her with 767,780 shares valued at about $48.75 million (a 1.29% ownership reduction).
- The sale is part of a recent string of insider disposals—about 90,000 shares (~$6.32M) in total—and was executed under a pre-arranged Rule 10b5-1 trading plan.
- Halozyme recently reported a ($0.24) EPS miss versus $1.92 expected while revenue rose 51.6% to $451.8M; analysts have a consensus "Hold" rating with a $78.56 price target.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $48,754,030. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00.
- On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00.
- On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $1,393,800.00.
- On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00.
- On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00.
Halozyme Therapeutics Stock Up 0.8%
Shares of HALO opened at $63.60 on Wednesday. The company has a 50-day simple moving average of $69.67 and a 200-day simple moving average of $69.09. The firm has a market capitalization of $7.53 billion, a P/E ratio of 25.54, a P/E/G ratio of 0.26 and a beta of 1.03. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same period last year, the company earned $1.26 EPS. The business's revenue for the quarter was up 51.6% on a year-over-year basis. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in HALO. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the period. Abel Hall LLC boosted its position in Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock valued at $216,000 after buying an additional 129 shares in the last quarter. StoneX Group Inc. increased its position in Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 132 shares during the period. Moran Wealth Management LLC increased its position in Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock valued at $2,396,000 after acquiring an additional 151 shares during the period. Finally, Campbell Newman Asset Management Inc. increased its position in Halozyme Therapeutics by 0.4% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company's stock valued at $2,705,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.
Wall Street Analysts Forecast Growth
HALO has been the topic of a number of recent research reports. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 21st. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Wells Fargo & Company raised their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a report on Thursday, February 19th. Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a research note on Tuesday, February 24th. Finally, TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $78.56.
Get Our Latest Report on HALO
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
